Magnesium sulfate is the ideal drug for the prevention and treatment of eclampsia. Nevertheless, the best regimen for protection against eclampsia with minimal side effects remains to be established. This study aimed to compare between intramuscular (IM) and intravenous (IV) magnesium sulfate regimes in severe preeclampsia and eclampsia in terms of efficacy, toxicity, maternal and fetal outcome.
Material & Methods: A prospective study will be performed on patients of eclampsia and severe preeclampsia admitted in mahila chikitsalya, J.L.N. Medical College, Ajmer during the period July 2019 to October 2019. We will compare IV and IM group, each group with equal number patients of eclampsia and severe pre-eclampsia.
Results: Average age being 23.62±3.74 years for group receiving IM regime 25.225±3.27 years for group receiving IV regime. We found 3 /40 (7.5%) patients with recurrence of fits of those who received the IM regime of MgSO4 and none of the patients who received IV regime had recurrence or occurrence of fits. In our study we found significantly higher incidence of signs of impending magnesium toxicity as of loss of DTR at creatinine levels >0.80 mg/dl.
Conclusion: We found that IV regime was significantly more efficacious in preventing recurrence or occurrence of seizures then IM regime. Percentage of caesarean section was more in IM regime With Increase in serum creatinine levels the significance of route of regime was increased with IV regime being safer.